Study #2017-0671
Clinical study to assess efficacy and safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Study Status
Open
Treatment Agent
Cyclophosphamide,Fludarabine,Interleukin-2,MDA-TIL
Principal Investigator
Amir A. Jazaeri
Description
If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if MDA-TIL can help to control pancreatic ductal adenocarcinoma, osteosarcoma, or ovarian cancer that is recurrent (has come back after treatment). MDA-TIL is made by collecting and growing specialized white blood cells (called T-cells) that are collected from your own tumor.
General Information
Disease Group: Malignant neoplasms of bone and articular cartilage,Malignant neoplasms of female genital organs,Malignant neoplasms of thyroid and other endocrine glands
Treatment Agent: Cyclophosphamide,Fludarabine,Interleukin-2,MDA-TIL
Treatment Location: Only at MDACC
Sponsor: Bristol-Myers Squibb,Iovance
Study Status
IRB Review and Approval Date: 08/17/2018
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms of bone and articular cartilage,Malignant neoplasms of female genital organs,Malignant neoplasms of thyroid and other endocrine glands
Study phase:
Phase II
Physician name:
Amir A. Jazaeri
Department:
Gynecologic Oncology
For general questions about clinical trials:
1-877-632-6789